Wegovy 0.5 mg Solution for injection
Authorisation EU/1/21/1608/002 · Novo Nordisk A/S
- Licence holder
- Novo Nordisk A/S (all products →)
- Active substance
- Semaglutide
- Clinical trials
- 136 clinical trials →
- Dosage form
- Solution for injection in pre-filled pen
- Route of administration
- Subcutaneous use
- ATC code
- A10BJ06
- First authorised
- 06/01/2022
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Semaglutide: supply and approvals
34 authorised products on the HPRA list contain Semaglutide. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
-
Rybelsus: Shortage resolved, first published 11 Jul 2023
Ozempic: Shortage resolved, first published 19 Oct 2022 - US shortage (FDA)
- Semaglutide Tablet: resolved, updated 4 Jun 2026
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 18 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 1608. It has been authorised for 4 years (since 6 January 2022). The HPRA list does not say whether it is on sale.
Other medicines with Semaglutide in Ireland
33 other products on the HPRA list contain Semaglutide, from 1 licence holder; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Kayshild 0.25 mg solution for injection in pre-filled pen | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Kayshild 0.5 mg solution for injection in pre-filled pen | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Kayshild 1 mg solution for injection in pre-filled pen | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Kayshild 1.7 mg solution for injection in pre-filled pen | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Kayshild 2.4 mg solution for injection in pre-filled pen | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Kyinsu (700 units + 2 mg)/mL solution for injection in pre-filled pen | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Ozempic 0.25 mg solution for injection in pre-filled pen | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Ozempic 0.5 mg solution for injection in pre-filled pen | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Ozempic 0.5 mg solution for injection in pre-filled pen | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Ozempic 1 mg solution for injection in pre-filled pen | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Ozempic 2 mg solution for injection in pre-filled pen | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Rybelsus 1.5 mg tablets | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
The licence holder
Novo Nordisk A/S holds 141 products on the HPRA list, with 21 different active substances; 10 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.